At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
Zoledronic acid +1 moredrug
Likely dose
Zoledronic acid 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prevention of Bone Loss After Acute SCI by Zoledronic Acid: Durability, Effect on Bone Strength, and Use of Biomarkers to Guide Therapy
In Brief
A Phase 2 clinical trial evaluating Zoledronic acid and Placebo for Spinal Cord Injury and 3 related conditions. Completed, enrolled 60 participants across 2 sites.
Detailed Summary
The overall objective of this study is to define an effective therapeutic approach, using currently available medication, to prevent or mitigate the loss of bone mass and bone strength that occurs after acute spinal cord injury.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSpinal Cord Injury, Acute Spinal Cord Injury, Bone Loss, Osteoporosis
CountriesUnited States
CollaboratorsCongressionally Directed Medical Research Programs
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 2014
Enrollment StartFeb 2015
Primary CompletionAug 2020
TodayJul 2026
First PostedDec 25, 2014
Enrollment StartFeb 1, 2015
Primary CompletionAug 25, 2020
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 11.5 years ago
Interventions
Zoledronic aciddrug
Intravenous infusion of zoledronic acid 5 mg.
Placebodrug
Placebo (saline) infusion to match zoledronic acid